MA42309A - Nouveau composé de tiacumicine pour régime posologique - Google Patents
Nouveau composé de tiacumicine pour régime posologiqueInfo
- Publication number
- MA42309A MA42309A MA042309A MA42309A MA42309A MA 42309 A MA42309 A MA 42309A MA 042309 A MA042309 A MA 042309A MA 42309 A MA42309 A MA 42309A MA 42309 A MA42309 A MA 42309A
- Authority
- MA
- Morocco
- Prior art keywords
- new
- dosage regime
- tiacumicin compound
- tiacumicin
- compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G01N33/56916—Enterobacteria, e.g. shigella, salmonella, klebsiella, serratia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Virology (AREA)
- Nutrition Science (AREA)
- Cell Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Physiology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15075021 | 2015-07-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA42309A true MA42309A (fr) | 2021-03-24 |
Family
ID=53672983
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA042309A MA42309A (fr) | 2015-07-03 | 2016-07-04 | Nouveau composé de tiacumicine pour régime posologique |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10548912B2 (fr) |
| EP (1) | EP3316892B1 (fr) |
| JP (3) | JP2018519344A (fr) |
| AU (1) | AU2016289307A1 (fr) |
| CA (1) | CA2990961A1 (fr) |
| EA (1) | EA034885B1 (fr) |
| IL (1) | IL256576B (fr) |
| MA (1) | MA42309A (fr) |
| WO (1) | WO2017005358A1 (fr) |
| ZA (1) | ZA201800217B (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11493262B2 (en) * | 2013-01-18 | 2022-11-08 | Triteq Lock And Security, L.L.C. | Cooler lock |
| US20200087390A1 (en) | 2016-12-21 | 2020-03-19 | Amgen Inc. | Anti-tnf alpha antibody formulations |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4918174A (en) | 1986-09-26 | 1990-04-17 | Abbott Laboratories | Tiacumicin compounds |
| US5583115A (en) | 1995-05-09 | 1996-12-10 | Abbott Laboratories | Dialkyltiacumicin compounds |
| US5767096A (en) | 1996-07-12 | 1998-06-16 | Abbott Laboratories | Bromotiacumicin compounds |
| US20070105791A1 (en) * | 2002-07-29 | 2007-05-10 | Optimer Pharmaceuticals, Inc. | Method of treating clostridium difficile-associated diarrhea |
| US7507564B2 (en) | 2002-07-29 | 2009-03-24 | Optimer Pharmaceuticals, Inc. | Tiacumicin production |
| US7378508B2 (en) | 2007-01-22 | 2008-05-27 | Optimer Pharmaceuticals, Inc. | Polymorphic crystalline forms of tiacumicin B |
| BRPI0519890A2 (pt) | 2005-01-31 | 2009-03-31 | Optimer Pharmaceuticals Inc | macrociclos de 18 elementos e seus análogos |
| US20120276060A1 (en) * | 2011-04-29 | 2012-11-01 | Techlab, Inc. | Fecal lactoferrin as a biomarker for determining disease severity and for treating infection in patients with clostridium difficile disease |
| KR20160149288A (ko) * | 2014-05-09 | 2016-12-27 | 아스텔라스 파마 유럽 리미티드 | 치료 요법 티아큐미신 화합물 |
-
2016
- 2016-07-04 JP JP2018500309A patent/JP2018519344A/ja active Pending
- 2016-07-04 EP EP16756939.1A patent/EP3316892B1/fr active Active
- 2016-07-04 WO PCT/EP2016/001140 patent/WO2017005358A1/fr not_active Ceased
- 2016-07-04 US US15/741,656 patent/US10548912B2/en not_active Expired - Fee Related
- 2016-07-04 EA EA201890101A patent/EA034885B1/ru unknown
- 2016-07-04 MA MA042309A patent/MA42309A/fr unknown
- 2016-07-04 AU AU2016289307A patent/AU2016289307A1/en not_active Abandoned
- 2016-07-04 CA CA2990961A patent/CA2990961A1/fr not_active Abandoned
-
2017
- 2017-12-25 IL IL256576A patent/IL256576B/en active IP Right Grant
-
2018
- 2018-01-11 ZA ZA2018/00217A patent/ZA201800217B/en unknown
-
2021
- 2021-08-19 JP JP2021133778A patent/JP7774401B2/ja active Active
-
2023
- 2023-09-08 JP JP2023146010A patent/JP2023182594A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021193088A (ja) | 2021-12-23 |
| JP2018519344A (ja) | 2018-07-19 |
| ZA201800217B (en) | 2019-06-26 |
| AU2016289307A1 (en) | 2018-01-18 |
| IL256576A (en) | 2018-02-28 |
| US10548912B2 (en) | 2020-02-04 |
| EP3316892B1 (fr) | 2023-07-19 |
| WO2017005358A1 (fr) | 2017-01-12 |
| IL256576B (en) | 2021-01-31 |
| EP3316892C0 (fr) | 2023-07-19 |
| CA2990961A1 (fr) | 2017-01-12 |
| EA201890101A1 (ru) | 2018-07-31 |
| EP3316892A1 (fr) | 2018-05-09 |
| EA034885B1 (ru) | 2020-04-02 |
| JP7774401B2 (ja) | 2025-11-21 |
| JP2023182594A (ja) | 2023-12-26 |
| US20180193370A1 (en) | 2018-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL258213B (en) | Pharmaceutical compounds | |
| EP3319606A4 (fr) | Composé pharmaceutique | |
| GB201504675D0 (en) | Pharmaceutical compounds | |
| GB201506658D0 (en) | Pharmaceutical compounds | |
| GB201414730D0 (en) | Pharmaceutical compound | |
| GB201519352D0 (en) | Pharmaceutical compounds | |
| GB201506660D0 (en) | Pharmaceutical compounds | |
| IL258246A (en) | Pharmaceutical compounds | |
| GB201506933D0 (en) | Pharmaceutical compounds | |
| GB201502567D0 (en) | Pharmaceutical compounds | |
| EP3349750A4 (fr) | Composé pharmaceutique | |
| IL257202B (en) | Compounds useful for ror–gamma–t inhibition | |
| LT3383385T (lt) | Melflufeno dozavimo režimas vėžio atveju | |
| IL253276A0 (en) | Anti-cancer compounds | |
| EP3298005C0 (fr) | Composés anti-cancereux | |
| SG11201708818VA (en) | Pharmaceutical compound | |
| SG11201708817XA (en) | Pharmaceutical compound | |
| FR3031123B1 (fr) | Montant pour cloison | |
| EP3345909A4 (fr) | Composé tétrahydrooxépinopyridine | |
| GB201517451D0 (en) | Pharmaceutical compounds | |
| GB201507883D0 (en) | Pharmaceutical compound | |
| GB201502156D0 (en) | Pharmaceutical compound | |
| TH1501007274A (th) | สารประกอบเบนโซไทโอฟิน (Benzothiophene Compound) | |
| GB201419570D0 (en) | Pharmaceutical compound | |
| GB201411215D0 (en) | Pharmaceutical compound |